Schroder participates in Epsilogen’s £30.75 million Series B funding round
LONDON, UK: Schroder UK Public Private Trust has made a £3.0 million investment in leading immunoglobulin E (IgE) antibodies developer, Epsilogen, as part of its £30.75 million Series B funding round. The round was led by a new investor, Novartis…